Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Dermatology Reports
Published in: Current Dermatology Reports 3/2016

01-09-2016 | Laser Therapy (J Jagdeo, Section Editor)

Current Advances in 5-Aminolevulinic Acid Mediated Photodynamic Therapy

Authors: Connor Thunshelle, Rui Yin, Qiquan Chen, Michael R. Hamblin

Published in: Current Dermatology Reports | Issue 3/2016

Login to get access

Abstract

Kennedy and Pottier discovered that photodynamic therapy (PDT) could be carried out using a procedure consisting of topical application of the porphyrin-precursor, 5-aminolevulinic acid (ALA) to the skin, followed after some time by illumination with various light parameters in the 1980s. Since then, ALA-PDT has expanded enormously and now covers most aspects of dermatological disease. The purpose of this review is to discuss a range of ingenious strategies that investigators have devised for improving the overall outcome (higher efficiency and lower side effects) of ALA-PDT. The big advance of using ALA esters instead of the free acid to improve skin penetration was conceived in the 1990s. A variety of more recent innovative approaches can be divided into three broad groups: (a) those relying on improving delivery or penetration of ALA into the skin; (b) those relying on ways to increase the synthesis of protoporphyrin IX inside the skin; (c) those relying on modification of the illumination parameters. In the first group, we have improved delivery of ALA with penetration-enhancing chemicals, iontophoresis, intracutaneous injection, or fractionated laser. There is also a large group of nanotechnology-related approaches with ALA being delivered using liposomes/ethosomes, ALA dendrimers, niosomes, mesoporous silica nanoparticles, conjugated gold nanoparticles, polymer nanoparticles, fullerene nanoparticles, and carbon nanotubes. In the second group, we can find the use of cellular differentiating agents, the use of iron chelators, and the effect of increasing the temperature. In the third group, we find methods designed to reduce pain as well as improve efficiency including fractionated light, daylight PDT, and wearable light sources for ambulatory PDT. This active area of research is expected to continue to provide a range of intriguing possibilities.
Literature
1.••
Krammer B, Plaetzer K. ALA and its clinical impact, from bench to bedside. Photochem Photobiol Sci. 2008;7(3):283–9. doi:10.​1039/​b712847a. Good comprehensive review of the development of ALA-PDT, and its range of clinical applications.PubMedCrossRef
2.
Berlin NI, Neuberger A, Scott JJ. The metabolism of delta-aminolaevulic acid. 1. Normal pathways, studied with the aid of 15N. Biochem J. 1956;64:80–90.PubMedPubMedCentralCrossRef
3.•
Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B. 1990;6(1–2):143–8. An early review by the original discoverers of ALA-PDT.PubMedCrossRef
4.••
Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A. Photoradiation therapy for the treatment of malignant tumors. Cancer Res. 1978;38(8):2628–35. An important landmark paper in the history of PDT used as a cancer therapy.PubMed
5.
Marcus SL, Dugan MH. Global status of clinical photodynamic therapy: the registration process for a new therapy. Lasers Surg Med. 1992;12(3):318–24.PubMedCrossRef
6.
Lang K, Schulte KW, Ruzicka T, Fritsch C. Aminolevulinic acid (Levulan) in photodynamic therapy of actinic keratoses. Skin Therapy Lett. 2001;6(10):1–2. 5.PubMed
7.
Gaullier JM, Berg K, Peng Q, Anholt H, Selbo PK, Ma LW, et al. Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture. Cancer Res. 1997;57(8):1481–6.PubMed
8.
9.
10.
de Blois AW, Grouls RJ, Ackerman EW, Wijdeven WJ. Development of a stable solution of 5-aminolaevulinic acid for intracutaneous injection in photodynamic therapy. Lasers Med Sci. 2002;17(3):208–15. doi:10.​1007/​s101030200030.PubMedCrossRef
11.
Sakamoto FH, Doukas AG, Farinelli WA, Tannous Z, Su Y, Smith NA, et al. Intracutaneous ALA photodynamic therapy: dose-dependent targeting of skin structures. Lasers Surg Med. 2011;43(7):621–31. doi:10.​1002/​lsm.​21073.PubMedCrossRef
12.
Haedersdal M, Sakamoto FH, Farinelli WA, Doukas AG, Tam J, Anderson RR. Pretreatment with ablative fractional laser changes kinetics and biodistribution of topical 5-aminolevulinic acid (ALA) and methyl aminolevulinate (MAL). Lasers Surg Med. 2014;46(6):462–9. doi:10.​1002/​lsm.​22259.PubMedCrossRef
13.
Lim HK, Jeong KH, Kim NI, Shin MK. Nonablative fractional laser as a tool to facilitate skin penetration of 5-aminolaevulinic acid with minimal skin disruption: a preliminary study. Br J Dermatol. 2014;170(6):1336–40. doi:10.​1111/​bjd.​12817.PubMedCrossRef
14.
Lippert J, Smucler R, Vlk M. Fractional carbon dioxide laser improves nodular basal cell carcinoma treatment with photodynamic therapy with methyl 5-aminolevulinate. Dermatol Surg. 2013;39(8):1202–8. doi:10.​1111/​dsu.​12242.PubMedCrossRef
15.
16.•
Forster B, Klein A, Szeimies RM, Maisch T. Penetration enhancement of two topical 5-aminolaevulinic acid formulations for photodynamic therapy by erbium:YAG laser ablation of the stratum corneum: continuous versus fractional ablation. Exp Dermatol. 2010;19(9):806–12. doi:10.​1111/​j.​1600-0625.​2010.​01093.​x. Shows that FRAXEL laser increases ALA penetration into the skin and enhances PPIX production.PubMedCrossRef
17.
18.
19.
De Rosa FS, Marchetti JM, Thomazini JA, Tedesco AC, Bentley MV. A vehicle for photodynamic therapy of skin cancer: influence of dimethylsulphoxide on 5-aminolevulinic acid in vitro cutaneous permeation and in vivo protoporphyrin IX accumulation determined by confocal microscopy. J Control Release. 2000;65(3):359–66.PubMedCrossRef
20.
21.
Fang YP, Huang YB, Wu PC, Tsai YH. Topical delivery of 5-aminolevulinic acid-encapsulated ethosomes in a hyperproliferative skin animal model using the CLSM technique to evaluate the penetration behavior. Eur J Pharm Biopharm. 2009;73(3):391–8. doi:10.​1016/​j.​ejpb.​2009.​07.​011.PubMedCrossRef
22.
Krishnan G, Roberts MS, Grice J, Anissimov YG, Benson HA. Enhanced transdermal delivery of 5-aminolevulinic acid and a dipeptide by iontophoresis. Biopolymers. 2011;96(2):166–71. doi:10.​1002/​bip.​21520.PubMedCrossRef
23.
24.
Piccioni A, Fargnoli MC, Schoinas S, Suppa M, Frascione P, Ginebri A, et al. Efficacy and tolerability of 5-aminolevulinic acid 0.5% liposomal spray and intense pulsed light in wrinkle reduction of photodamaged skin. J Dermatolog Treat. 2011;22(5):247–53. doi:10.​3109/​09546634.​2011.​590791.PubMedCrossRef
25.
26.
27.
28.
29.
30.
Gomez C, Benito M, Katime I, Teijon JM, Blanco MD. In vitro transdermal and biological evaluation of ALA-loaded poly(N-isopropylacrylamide) and poly(N-isopropylacrylamide-co-acrylic acid) microgels for photodynamic therapy. J Microencapsul. 2012;29(7):626–35. doi:10.​3109/​02652048.​2012.​676091.PubMedCrossRef
31.
Ma X, Qu Q, Zhao Y. Targeted delivery of 5-aminolevulinic acid by multifunctional hollow mesoporous silica nanoparticles for photodynamic skin cancer therapy. ACS Appl Mater Interfaces. 2015;7(20):10671–6. doi:10.​1021/​acsami.​5b03087.PubMedCrossRef
32.
33.
de Oliveira Goncalves K, da Silva MN, Sicchieri LB, de Oliveira Silva FR, de Matos RA, Courrol LC. Aminolevulinic acid with gold nanoparticles: a novel theranostic agent for atherosclerosis. Analyst. 2015;140(6):1974–80. doi:10.​1039/​c4an02166e.PubMedCrossRef
34.
Hadizadeh M, Fateh M. Synergistic cytotoxic effect of gold nanoparticles and 5-aminolevulinic acid-mediated photodynamic therapy against skin cancer cells. Iran J Med Sci. 2014;39(5):452–8.PubMedPubMedCentral
35.
Mohammadi Z, Sazgarnia A, Rajabi O, Soudmand S, Esmaily H, Sadeghi HR. An in vitro study on the photosensitivity of 5-aminolevulinic acid conjugated gold nanoparticles. Photodiagn Photodyn Ther. 2013;10(4):382–8. doi:10.​1016/​j.​pdpdt.​2013.​03.​010.CrossRef
36.
Benito M, Martin V, Blanco MD, Teijon JM, Gomez C. Cooperative effect of 5-aminolevulinic acid and gold nanoparticles for photodynamic therapy of cancer. J Pharm Sci. 2013;102(8):2760–9. doi:10.​1002/​jps.​23621.PubMedCrossRef
37.
Li Z, Pan LL, Zhang FL, Zhu XL, Liu Y, Zhang ZZ. 5-Aminolevulinic acid-loaded fullerene nanoparticles for in vitro and in vivo photodynamic therapy. Photochem Photobiol. 2014;90(5):1144–9. doi:10.​1111/​php.​12299.PubMed
38.••
Battah S, O’Neill S, Edwards C, Balaratnam S, Dobbin P, MacRobert AJ. Enhanced porphyrin accumulation using dendritic derivatives of 5-aminolaevulinic acid for photodynamic therapy: an in vitro study. Int J Biochem Cell Biol. 2006;38(8):1382–92. doi:10.​1016/​j.​biocel.​2006.​02.​001. Important paper showing that ALA-dendrimers can enhance ALA delivery and improve PDT killing after illumination.PubMedCrossRef
39.
Battah SH, Chee CE, Nakanishi H, Gerscher S, MacRobert AJ, Edwards C. Synthesis and biological studies of 5-aminolevulinic acid-containing dendrimers for photodynamic therapy. Bioconjug Chem. 2001;12(6):980–8.PubMedCrossRef
40.
Rodriguez L, Vallecorsa P, Battah S, Di Venosa G, Calvo G, Mamone L, et al. Aminolevulinic acid dendrimers in photodynamic treatment of cancer and atheromatous disease. Photochem Photobiol Sci. 2015;14(9):1617–27. doi:10.​1039/​c5pp00126a.PubMedCrossRef
41.
42.
Blake E, Allen J, Curnow A. The effects of protoporphyrin IX-induced photodynamic therapy with and without iron chelation on human squamous carcinoma cells cultured under normoxic, hypoxic and hyperoxic conditions. Photodiagn Photodyn Ther. 2013;10(4):575–82. doi:10.​1016/​j.​pdpdt.​2013.​06.​006.CrossRef
43.•
Blake E, Allen J, Curnow A. An in vitro comparison of the effects of the iron-chelating agents, CP94 and dexrazoxane, on protoporphyrin IX accumulation for photodynamic therapy and/or fluorescence guided resection. Photochem Photobiol. 2011;87(6):1419–26. doi:10.​1111/​j.​1751-1097.​2011.​00985.​x. Compares different iron chelating agents for increasing PPIX synthesis after application of ALA.PubMedCrossRef
44.
Liu HF, Xu SZ, Zhang CR. Influence of CaNa2 EDTA on topical 5-aminolaevulinic acid photodynamic therapy. Chin Med J. 2004;117(6):922–6.PubMed
45.
Yang J, Xia Y, Liu X, Jiang S, Xiong L. Desferrioxamine shows different potentials for enhancing 5-aminolaevulinic acid-based photodynamic therapy in several cutaneous cell lines. Lasers Med Sci. 2010;25(2):251–7. doi:10.​1007/​s10103-009-0721-0.PubMedCrossRef
46.
47.
48.•
Malik Z, Ehrenberg B, Faraggi A. Inactivation of erythrocytic, lymphocytic and myelocytic leukemic cells by photoexcitation of endogenous porphyrins. J Photochem Photobiol B. 1989;4(2):195–205. Another early report describing the observations that would lead to ALA-PDT.PubMedCrossRef
49.•
Ortel B, Chen N, Brissette J, Dotto GP, Maytin E, Hasan T. Differentiation-specific increase in ALA-induced protoporphyrin IX accumulation in primary mouse keratinocytes. Br J Cancer. 1998;77(11):1744–51. First report that differentiation can increase PPIX formation by up-regulating coproporphyrinogen oxidase.PubMedPubMedCentralCrossRef
50.
51.
52.
Rollakanti KR, Anand S, Davis SC, Pogue BW, Maytin EV. Noninvasive optical imaging of UV-induced squamous cell carcinoma in murine skin: studies of early tumor development and vitamin D enhancement of protoporphyrin IX production. Photochem Photobiol. 2015. doi:10.​1111/​php.​12503.PubMed
53.
Galitzer BI. Effect of retinoid pretreatment on outcomes of patients treated by photodynamic therapy for actinic keratosis of the hand and forearm. J Drugs Dermatol. 2011;10(10):1124–32.PubMed
54.
55.
Moan J, Berg K, Gadmar OB, Iani V, Ma L, Juzenas P. The temperature dependence of protoporphyrin IX production in cells and tissues. Photochem Photobiol. 1999;70(4):669–73.PubMedCrossRef
56.
Juzenas P, Sorensen R, Iani V, Moan J. Uptake of topically applied 5-aminolevulinic acid and production of protoporphyrin IX in normal mouse skin: dependence on skin temperature. Photochem Photobiol. 1999;69(4):478–81.PubMedCrossRef
57.
58.
Mamalis A, Koo E, Sckisel GD, Siegel DM, Jagdeo J. The temperature-dependent impact of thermal-ALA-PDT on apoptosis and reactive oxygen species generation in human dermal fibroblasts. Br J Dermatol. 2016. doi:10.​1111/​bjd.​14509.PubMed
59.
De Vijlder HC, Middelburg T, De Bruijn HS, Martino Neumann HA, Sterenborg HC, Robinson DJ, et al. Optimizing ALA-PDT in the management of non-melanoma skin cancer by fractionated illumination. G Ital Dermatol Venereol. 2009;144(4):433–9.PubMed
60.
van der Veen N, van Leengoed HL, Star WM. In vivo fluorescence kinetics and photodynamic therapy using 5-aminolaevulinic acid-induced porphyrin: increased damage after multiple irradiations. Br J Cancer. 1994;70(5):867–72.PubMedPubMedCentralCrossRef
61.•
de Vijlder HC, Sterenborg HJ, Neumann HA, Robinson DJ, de Haas ER. Light fractionation significantly improves the response of superficial basal cell carcinoma to aminolaevulinic acid photodynamic therapy: five-year follow-up of a randomized, prospective trial. Acta Derm Venereol. 2012;92(6):641–7. doi:10.​2340/​00015555-1448. Clinical study showing that fractionated light delivery improves ALA-PDT outcome.PubMedCrossRef
62.
Sotiriou E, Apalla Z, Chovarda E, Goussi C, Trigoni A, Ioannides D. Single vs. fractionated photodynamic therapy for face and scalp actinic keratoses: a randomized, intraindividual comparison trial with 12-month follow-up. J Eur Acad Dermatol Venereol. 2012;26(1):36–40. doi:10.​1111/​j.​1468-3083.​2011.​04003.​x.PubMedCrossRef
63.
de Bruijn HS, Casas AG, Di Venosa G, Gandara L, Sterenborg HJ, Batlle A, et al. Light fractionated ALA-PDT enhances therapeutic efficacy in vitro; the influence of PpIX concentration and illumination parameters. Photochem Photobiol Sci. 2013;12(2):241–5. doi:10.​1039/​c2pp25287b.PubMedCrossRef
64.•
de Bruijn HS, Brooks S, van der Ploeg-van den Heuvel A, Ten Hagen TL, de Haas ER, Robinson DJ. Light Fractionation significantly increases the efficacy of photodynamic therapy using BF-200 ALA in normal mouse skin. PLoS ONE. 2016;11(2):e0148850. doi:10.​1371/​journal.​pone.​0148850. Clinical study showing that daylight-mediated ALA-PDT performs equally well to red light, but is better tolerated.PubMedPubMedCentralCrossRef
65.
66.
Rubel DM, Spelman L, Murrell DF, See JA, Hewitt D, Foley P, et al. Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial. Br J Dermatol. 2014;171(5):1164–71. doi:10.​1111/​bjd.​13138.PubMedCrossRef
67.
68.
Attili SK, Lesar A, McNeill A, Camacho-Lopez M, Moseley H, Ibbotson S, et al. An open pilot study of ambulatory photodynamic therapy using a wearable low-irradiance organic light-emitting diode light source in the treatment of nonmelanoma skin cancer. Br J Dermatol. 2009;161(1):170–3. doi:10.​1111/​j.​1365-2133.​2009.​09096.​x.PubMedCrossRef
69.
70.
Ferrick B, Izikson L, Ibrahimi O, Jalian HR, Kroshinsky D, Anderson RR, et al. Quantitative volumetric changes after conventional ALA-PDT compared to a new inhibitory PDT method (i-PDT) to reduce inflammation in a preliminary study. Lasers Surg Med. 2014;46(S25):43–4.
Metadata
Title
Current Advances in 5-Aminolevulinic Acid Mediated Photodynamic Therapy
Authors
Connor Thunshelle
Rui Yin
Qiquan Chen
Michael R. Hamblin
Publication date
01-09-2016
Publisher
Springer US
Published in
Current Dermatology Reports / Issue 3/2016
Electronic ISSN: 2162-4933
DOI
https://doi.org/10.1007/s13671-016-0154-5

Other articles of this Issue 3/2016

Current Dermatology Reports 3/2016 Go to the issue

Medical Surgery (M Alam, Section Editor)

Premedication, Sedation, and Pain Medication in Dermatologic Surgery

Laser Therapy (J Jagdeo, Section Editor)

How Wounding via Lasers Has Potential Photocarcinogenic Preventative Effects via Dermal Remodeling

Laser Therapy (J Jagdeo, Section Editor)

Accelerating Ablative Fractional Resurfacing Wound Healing Recovery by Photobiomodulation

Laser Therapy (J Jagdeo, Section Editor)

The Evolution and Current Best Treatments for Traumatic, Surgical, and Burn Scars

Laser Therapy (J Jagdeo, Section Editor)

Tattoos and Beyond: the Clinical Evolution of Picosecond Laser Technology

Laser Therapy (J Jagdeo, Section Editor)

A Combination Approach with Lasers, Light, and Energy-Based Devices for Ultimate Rejuvenation of the Aging Face